|
Synonyms: ACTIMAB® | HuM195 | SGN-33 | SMART M195
Compound class:
Antibody
Comment: Lintuzumab is a monoclonal antibody directed against CD33, a surface antigen found on myeloid leukemia cells. A modified version of lintuzumab that is conjugated with the chelator satetraxetan to facilitate actinium (225Ac) radiolabelling (a radioimmunotherapeutic) has been developed (see Patent US6670456 [4] and IMGT/mAb-db ID 936). 225Ac emits α particles and is used as these cause less nonspecific cytotoxicity than β particles (i.e. decreased killing of bystander cells). 225Ac has been termed a 'nano-generator' as for each decay producing a high-energy α particle, a series of daughter atoms generate additional α particles, effectively amplifying the radioactive dose at the target site. Lintuzumab is a humanized version of the murine anti-CD33 antibody, M195 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Lintuzumab is an immune checkpoint modulator. |
